Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers

Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers - Monocentric Prospective Cohort

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00767182

Acronym

VOLUPLA

Enrollment

Registered

2008-10-06

Start date

2008-08-31

Completion date

2009-08-31

Last updated

2016-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Vascular Malformation

Keywords

preeclampsia, eclampsia, retroplacental hematoma, vascular IUGR, IUFD, placental volume

Brief summary

Pregnancy complications called PVP are mainly responsible for perinatal mortality. In these cases, the placenta is smaller and often the centre of thrombotic lesions. The estimation of the placenta volume by 3D ultrasound coupled with growth factors and D-Dimers measures could improve the understanding of these pathologies to optimize their detection.

Detailed description

Pregnancy complications called Placental Vascular Pathologies (PVP) are mainly responsible for perinatal mortality. In these cases, the placenta is smaller and often the centre of thrombotic lesions. The estimation of the placenta volume by 3D ultrasound coupled with growth factors and D-Dimers measures could improve the understanding of these pathologies to optimize their detection. Thus, the identification of predictive factors of the risk of occurrence or recurrence of PVP could allow us to propose a monitoring of patients at risk, to anticipate corticoids administration for the foetuses pulmonary maturation and perhaps later to adapt anti hypertensive and antithrombotic therapeutics.

Interventions

OTHERblood sample

biological markers evaluated : D-Dimer, sEPCR

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* previous history of one or more PVC episodes : preeclampsia, HELLPs, retroplacental hematoma, vascular IUGR\<10th percentile, recurrence miscarriage \>2, unexplained IUFD or IUFD after abruption placentae, eclampsia. * coming for a 12 weeks ultrasound

Exclusion criteria

* Multiple pregnancy * past history of in utero fetal death due to congenital malformations, rhesus incompatibility or an infection * previous history of IUGR which etiology was a chromosomal, genic or infectious anomaly

Design outcomes

Primary

Measure	Time frame
placental volume by 3D ultrasound and D-Dimers rate	Week 12

Secondary

Measure	Time frame
EPCRs rate measurements	Week 12
Occurrence or recurrence of PVP	Week 12
placental volume by 3D ultrasound and D-Dimers rate	Week 16

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026